Data Safety Monitoring Board (DSMB) Charter — GLPI103-301
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The Data Safety Monitoring Board charter — the mandate and procedures of the independent board overseeing subject safety.
Why it exists. For a blinded trial, an independent DSMB reviews unblinded safety data periodically and can recommend stopping or modifying the trial. The charter defines its membership, meeting schedule, and decision rules in advance.
How it is produced here. It is an operational trial document — a plan, charter, or template of the kind kept in the Trial Master File. It describes how the trial is run, rather than reporting the trial's results.
Format & governing standard. FDA DMC guidance; EMA; ICH E6(R3)
Data Safety Monitoring Board (DSMB) Charter — GLPI103-301
| Field | Value |
|---|---|
| Document ID | TMF-DSMB |
| Version | 2.0 (full) |
| Study No. | GLPI103-301 |
| Standard | FDA DMC guidance; EMA; ICH E6(R3) |
| Confidentiality | Confidential — TMF |
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Clinical / PV | Initial charter |
| 2.0 | 2026-06-29 | Clinical / PV | Full charter — composition, procedures, data flow, stopping guidance |
1. Purpose
The DSMB (IDMC) is an independent body that periodically reviews accumulating unblinded safety data (and any interim efficacy) to protect participants and study integrity.
2. Composition & Independence
The Data Safety Monitoring Board is a group of outside experts — not the sponsor — who are allowed to see unblinded safety data during the trial. Their independence is what lets them recommend pausing or stopping the study purely in the subjects' interest.
≥3 voting independent members: an endocrinologist/diabetologist, a cardiologist (mechanism-relevant), and an independent biostatistician; a voting Chair. Members have no financial/intellectual conflicts and are independent of the sponsor study team. An independent unblinded statistician (not a board member) prepares closed reports.
3. Responsibilities
- Review TEAEs, AESIs (GI, pancreatitis, MTC, hypoglycaemia, cardiovascular/heart-rate), SAEs, deaths, discontinuations, and relevant laboratory trends.
- Assess benefit–risk and recommend continue / modify / pause / stop.
- Review any interim analysis per SAP-301.
4. Meetings & Data Flow
Organizational meeting before first subject; safety reviews at predefined enrollment/exposure milestones (e.g., ~25%, 50%, 75% enrolled) and ad hoc for emerging signals. Open session (sponsor may attend) + closed session (unblinded; board + independent statistician only). Recommendations are minuted (TMF-DSMB-MIN).
5. Stopping Guidance
The rules for stopping early — for harm, for overwhelming benefit, or for futility — are written before the trial starts, so a hard decision is guided by pre-agreed criteria rather than made up under pressure.
Considerations for unacceptable safety (e.g., excess SAEs, pancreatitis cluster, cardiovascular signal, severe hypoglycaemia imbalance). Any interim efficacy/futility would use pre-specified statistical boundaries (alpha spending; SAP-301 §11). Recommendations are advisory to the sponsor.
6. Confidentiality & Records
Members maintain strict confidentiality; unblinded outputs are restricted; minutes (open/closed) are retained in the TMF. Operating procedures and quorum (majority; Chair tie-break) are defined herein.
Comments (0)
No comments yet. Be the first to say something!